Memantine hydrochloride
Memantine Orion contains the active substance memantine hydrochloride. It belongs to a group of medicines called anti-dementia medicines.
Memory loss in Alzheimer's disease is due to a disturbance of message signals in the brain. The brain contains so-called N-methyl-D-aspartate (NMDA) receptors that are involved in the transmission of nerve signals that are important for learning and memory.
Memantine Orion belongs to a group of medicines called NMDA receptor antagonists.
Memantine Orion works by improving the transmission of nerve signals and memory.
Memantine Orion is used to treat patients with moderate to severe Alzheimer's disease.
Before taking Memantine Orion, discuss with your doctor or pharmacist:
During treatment with memantine, your doctor should regularly monitor your kidney function and, if necessary, adjust the dose of the medicine.
Avoid taking other medicines such as amantadine (for Parkinson's disease), ketamine (an anesthetic), dextromethorphan (for cough), and other NMDA receptor antagonists.
Do notgive Memantine Orion to children and adolescents under 18 years of age.
Tell your doctor or pharmacist about all medicines you are taking now or have recently taken, and about any medicines you plan to take.
In particular, taking Memantine Orion may affect the action of, and may require dose adjustment by your doctor, the following medicines:
If you are hospitalized, inform your doctor that you are taking Memantine Orion.
Tell your doctor if you have recently changed your diet (e.g., switched from a normal diet to a strict vegetarian diet) or have been diagnosed with renal tubular acidosis (excessive concentration of acidic substances in the blood due to kidney dysfunction) or severe urinary tract infections (structures through which urine flows). In these cases, your doctor may need to adjust the dose of the medicine.
Pregnancy and breastfeedingIf you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medicine.
Pregnancy
Do nottake memantine if you are pregnant.
Breastfeeding
Women taking Memantine Orion should not breastfeed.
Your doctor will inform you whether your illness allows you to drive or use machines safely. Memantine Orion may also affect your reaction speed, making it inadvisable to drive or use machines.
Always take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The recommended dose of Memantine Orion for adults and the elderly is 20 mg once daily. To reduce the risk of side effects, the dose of the medicine should be increased gradually, according to the following scheme:
Week 1 (days 1-7):
Take half a 10 mg coated tablet (5 mg) once daily for 7 days.
Week 2 (days 8-14):
Take one 10 mg coated tablet (10 mg) once daily for 7 days.
Week 3 (days 15-21):
Take one and a half 10 mg coated tablets (15 mg) once daily for 7 days.
From week 4 (days 22-28 and onwards):
Take two 10 mg coated tablets (20 mg) or one 20 mg coated tablet once daily for 7 days.
The recommended maintenance dose is 20 mg once daily.
To continue treatment, consult your doctor.
In patients with impaired renal function, the dose of the medicine is determined by the doctor.
In such cases, regular monitoring of renal function is necessary, at intervals determined by the doctor.
Memantine Orion should be taken orally, once daily. To ensure the effectiveness of treatment, the medicine should be taken regularly, at the same time every day. The tablets should be swallowed with water.
The tablets can be taken with or without food.
Treatment should be continued as long as it is effective. Your doctor will regularly assess the effectiveness of treatment.
| half a 10 mg coated tablet once daily |
| one 10 mg coated tablet once daily |
| one and a half 10 mg coated tablets once daily |
| two 10 mg coated tablets or one 20 mg coated tablet once daily |
If you have any further questions about taking this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Generally, the observed side effects are mild to moderate.
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 10,000 people):
Not known (frequency cannot be estimated from the available data):
Alzheimer's disease is associated with depression, suicidal thoughts, and suicide. Such cases have been reported in patients treated with Memantine Orion.
If you experience any side effects, including any not listed in this leaflet, please tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products,
Aleje Jerozolimskie 181 C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: + 48 22 49 21 309,
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after "EXP". The expiry date refers to the last day of that month.
Store in the original package to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Memantine Orion 10 mg coated tablets are white to almost white, oval, biconvex, film-coated tablets with a size of approximately 13.0 x 5.5 mm, with the imprint "10" on one side and a break line on the other side. The tablet can be divided into equal doses.
Memantine Orion 20 mg coated tablets are light red to reddish, oval, biconvex, film-coated tablets with a size of approximately 15.3 x 6.2 mm, with the imprint "20" on one side and a smooth surface on the other side.
Memantine Orion is available in blister packs (PVC/PVDC/Aluminum).
Pack sizes: 28, 30, 50, 56, 98, or 100 tablets in a cardboard box.
Orion Corporation, Orionintie 1, FI-02200 Espoo, Finland
Orion Corporation, Orion Pharma
Orionintie 1
FI-02200 Espoo
Finland
Orion Corporation, Orion Pharma
Joensuunkatu 7
FI-24100 Salo
Finland
To obtain more detailed information on this medicine, contact the local representative of the marketing authorization holder:
Orion Pharma Poland Sp. z o. o.
kontakt@orionpharma.info.pl
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.